Carole Ho

EVP and President, Lilly Neuroscience

Other Other Board Member Board Member

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer and Head of Development (until November 14, 2025)	$483,000	—	$1,151,867	$2,180,003	—	$14,000	$3,828,870
2024	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$535,600	$337,416	$1,092,128	$2,043,815	—	$13,800	$4,022,759
2023	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$520,000	$269,093	$1,136,146	$2,230,744	—	$13,200	$4,169,183
2022	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$500,000	$225,000	$2,307,095	$2,647,757	—	$12,200	$5,692,052
2021	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$473,616	$284,170	$2,125,800	$3,648,420	—	$11,600	$6,543,606
2020	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$457,600	$366,080	$1,382,774	$2,107,493	—	$11,400	$4,325,347
2019	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$440,000	$176,000	$305,830	$1,558,941	—	$8,800	$2,489,571
2018	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$423,124	$371,187	$179,673	$2,948,616	—	$12,869	$3,935,469
2017	Denali Therapeutics Inc. (DNLI)	Chief Medical Officer	$406,850	$203,425	—	$746,025	—	$11,697	$1,367,997

Executive changes

Resigned Board of Directors at Beam Therapeutics Inc. (BEAM)
2026-02-27
Appointed member of the Board of Directors at Royalty Pharma plc (RPRX)
2025-07-17

Earnings-call appearances

No earnings-call appearances recorded yet.